肿瘤细胞治疗研究
FRONTIER PAPERS
Next-generation antibody-based therapeutics in cancer: antibody-drug conjugates bispecific antibodies across hematologic malignancies and solid tumors
肿瘤学的治疗范式正在经历由抗体药物偶联物（ADC）和双特异性抗体（bsAb）驱动的深刻变革。
A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study.
这些结果提示，CAR-NKG2A技术可能克服HVGR，尤其是在NK细胞上NKG2A表达升高的患者中。
CAR-Engineered Cell Therapies Beyond Cancer: Reprogramming Fibrosis and Immune-Mediated Inflammation.
嵌合抗原受体（CAR）工程化细胞疗法正从血液系统恶性肿瘤拓展至自身免疫性、炎症性和纤维化疾病，尽管各平台和适应证的证据成熟度差异显著。
Anti-BCMA/GPRC5D CAR T cells in patients with relapsed or refractory multiple myeloma who have extraosseous extramedullary disease.
这些发现支持抗 BCMA/GPRC5D 双特异性 CAR T 细胞在伴骨外 EMD 的复发/难治性多发性骨髓瘤（RRMM）患者中诱导了高缓解率，且安全性可控。
Subsequent CAR-T and engineered antibody for relapsed/refractory multiple myeloma following BCMA-targeted treatment: a systematic review and meta-anal
GPRC5D CAR-T 在 BCMA 治疗后场景中显示出优于工程化抗体的疗效。
Emerging therapeutic advances for immune thrombocytopenia: highlights from selected early‑phase and pivotal trials at the 2025 ASH annual meeting.
本通讯重点介绍了 2025 ASH 年会上报告的免疫性血小板减少症 (ITP) 新兴免疫靶向疗法。
Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of relapsed/refractory multiple myeloma.
CD74 参与 R/R MM 的免疫逃逸和 CAR-T 耐药。
B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C grou
抗BCMA CAR T细胞疗法对anti-GPRC5D CAR T细胞疗法治疗失败后的RRMM有效，且安全性可接受。
The PPTC7/BNIP3/NIX axis induces cGAS/STING-mediated senescence and augments CAR-T efficacy by repressing tumor-intrinsic mitophagy.
我们的研究结果定义了一条肿瘤内在的 PPTC7-BNIP3/NIX-mtDNA-cGAS/STING 回路，其中抑制线粒体自噬可增加肿瘤免疫原性并使 MM 对 CAR-T 治疗敏感，凸显 PPTC7 作为潜在免疫增敏靶点以克服 CAR-T 耐药。
Nanomedicine-Empowered CAR-T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy.
多发性骨髓瘤（MM）仍是一种难以治愈的血液系统恶性肿瘤。
MEMBER ACCOUNT
登录成功会直接打开下一页。
